BerGenBio ASA Initiates Fully Underwritten Rights Issue
BerGenBio ASA has officially announced an innovative and fully underwritten rights issue aimed at its existing shareholders, coinciding with its recent merger efforts. This strategic move is designed to raise gross proceeds of approximately NOK 130 million, supported by a strong consortium of underwriters comprising significant shareholders and external partners. This rights issue, to be executed post-merger, is a vital part of BerGenBio's ongoing efforts to advance research and development in cancer therapies.
Understanding the Rights Issue and Merger Context
The fully underwritten rights issue follows the proposed merger with Oncoinvent ASA, a strategic decision aimed at strengthening their combined position in the biotechnology sector. The completion of this merger is expected to enhance BerGenBio's research capabilities, especially in the area of innovative cancer treatments, including the potent Radspherin therapy.
Proceeds Allocation and Milestones
The funds generated from this rights issue will be pivotal in achieving significant milestones. The combined company aims at important clinical trial completions and data readouts that can propel their research. Key milestones include:
- Final Phase 1 ovarian cancer data expected within the second half of 2025.
- Complete Phase 2 recruitment, involving 96 patients, for ongoing trials targeting peritoneal metastases from ovarian cancer.
- Interim Phase 2 data collection at the 9-month follow-up anticipated for early 2026.
- Beginning of an external manufacturing scale-up program for Radspherin.
Through these initiatives, BerGenBio intends to extend its financial runway into 2027, consolidating its research pipeline and operational capabilities.
Conditions and Expectations Surrounding the Rights Issue
The rights issue is contingent on several critical approvals, primarily from shareholders, who will convene at an extraordinary general meeting (EGM) to vote on the proposal. This meeting, tentatively slated for August, will be crucial in determining the trajectory of the rights issue and securing the necessary backing for the merger with Oncoinvent.
Furthermore, the company plans to publish a comprehensive prospectus approved by the Norwegian Financial Supervisory Authority, outlining all relevant terms and conditions associated with the rights issue. The aim is to ensure transparency and provide shareholders with the necessary information to make informed decisions.
Leadership and Management Preparedness
To facilitate the rights issue, BerGenBio has appointed ABG Sundal Collier ASA and DNB Carnegie as joint lead managers and bookrunners. These firms bring a wealth of experience to the table, guiding the company through this critical phase. The involvement of seasoned professionals from both companies increases confidence among investors and stakeholders regarding the rights issue's execution.
Importance of Synergy Between BerGenBio and Oncoinvent
The merger with Oncoinvent is viewed as a substantial advance for BerGenBio, potentially unlocking further resources and expertise in developing radiopharmaceutical therapies. Oncoinvent’s Radspherin therapy shows promise in treating cancer with limited side effects, setting the stage for a collaboration that could revolutionize treatment options in the oncology space.
Future Perspectives on the Rights Issue Impact
As BerGenBio navigates through this pivotal period, the rights issue stands out as a cornerstone of its strategy. By inviting existing shareholders to participate actively in this venture, BerGenBio is not just seeking capital; it is looking to build a community of investors committed to the success of its groundbreaking research and contributions to oncology.
Frequently Asked Questions
What is BerGenBio's rights issue about?
The rights issue is aimed at raising NOK 130 million to support ongoing research and the merger with Oncoinvent ASA, focusing on innovative cancer therapies.
When will the rights issue occur?
The rights issue is expected to be implemented around October 2025, after the completion of the merger between BerGenBio and Oncoinvent.
Who is managing the rights issue?
ABG Sundal Collier ASA and DNB Carnegie have been engaged as the joint lead managers and bookrunners for the rights issue, ensuring proper execution.
What are the key milestones targeted with the funding?
The funding aims to reach significant clinical trial milestones and support operational developments necessary for growth in the oncology sector.
How will shareholders be involved in the rights issue?
Eligible shareholders will receive tradable subscription rights, allowing them to subscribe for new shares in proportion to existing holdings during the subscription period.
